CRTE7A2-01 TCR-T Cell Therapy (Corregene)

N/A

Report date: 2023/11/21 13:27:47
First In Class

Base Information

Drug NameCRTE7A2-01 TCR-T Cell Therapy (Corregene)
Drug Alias NameCRTE7A2-01
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionProtein E7 modulatorsProtein E6 modulators
TargetsProtein E7Protein E6
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsHead and Neck Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCorregene Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCorregene Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursUterine Cervical NeoplasmsHead and Neck Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A